Compare VanEck Gold Miners ETF (GDX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Johnson & Johnson — how do they compare? VanEck Gold Miners ETF trades at $89.23 (market cap $25.65B), while Johnson & Johnson trades at $260.72 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 24.1× VanEck Gold Miners ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Johnson & Johnson for 129 Days on average.
| GDX | JNJ | |
|---|---|---|
Market Cap | $25.65B | $618.09B |
Volume | 16,534,046 | 6,050,983 |
52-Week High | $115.84 | $278.43 |
52-Week Low | $68.28 | $186.00 |
Typical Hold Time | 76 Days | 129 Days |
Sector | — | Health |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.24, up 4.42% today but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with Allworth Financial and HB Wealth Management reducing positions while Ameritas Advisory Services increased its stake by 315.7%.
Gold miners offer leverage to gold prices but face volatility from interest rate sensitivity and operational risks. Current technical weakness suggests near-term pressure, though long-term fundamentals remain supported by gold's defensive characteristics amid macroeconomic uncertainty. The divergence between physical gold performance and miner valuations presents both risk and opportunity for investors.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
